Progenitor Cell Therapy Adds Development and Manufacturing Expertise

Share Article

Marta Schilling joins Progenitor Cell Therapy as Director of its West Coast Manufacturing Operations.

Progenitor Cell Therapy, LLC (PCT) announced today the addition of Ms. Marta Schilling as its Director of Manufacturing Operations (West Coast). Marta Schilling is a cellular therapy specialist with over 20 years of experience spanning corporate research, development, clinical trials, customer training and support, and cGMP cell therapy manufacturing.

Prior to joining PCT, Ms. Schilling was the Associate Director of the Cell Processing Laboratory at IDM Pharma in Irvine, California where she was instrumental in setting up the cGMP manufacturing facility and systems. Marta was also one of the primary contributors to significant process improvements for producing IDM's autologous dendritic cell vaccines in Phase I/II clinical trials.

Marta began her cell therapy career with Baxter Healthcare and later joined Nexell Therapeutics where she was involved in the research, development and customer support of the Isolex® CD34 Cell Selection System and the CytoMate® Cell Washer Device. Her responsibilities included supporting customers throughout the United States, Canada, Europe, Singapore, Japan and Australia.

"Over the course of her career, Ms. Schilling has personally trained and supported many of the pioneers in cell therapy," states PCT President Robert A. Preti, PhD. "She brings to PCT a large network of peers and vast understanding of the technical issues in this evolving field."

Dr. Andrew L. Pecora, PCT's CEO and Board Chairman states, "With the addition of Marta, Progenitor Cell Therapy's management team now has over 125 years of combined experience in cell therapy, with participation in over 60 regulatory filings in the US and Europe and development of seven cGMP facilities. The company has served over 100 clients, performed over 30,000 cell therapy procedures involving over 17,000 units of 20+ different kinds of cell-based products, approximately 5,000 of which have already been used for patient treatment."

"The addition of Ms. Schilling," continues Dr. Pecora, "is part of our ongoing commitment to build a team with unrivaled experience in the development, production and commercialization of cell therapy treatments."

Ms. Schilling was awarded her Bachelor of Science degree in Medical Technology, specializing in Hematology, from the University of Vermont. She has presented her work in numerous peer-reviewed scientific journals and at international meetings.

About Progenitor Cell Therapy, LLC.
Progenitor Cell Therapy, LLC (PCT) is a client-based company providing cell therapy service solutions for the research, development, manufacture and commercialization of cell-based therapies. With its cell therapy manufacturing facilities and team of experienced professionals, PCT provides current Good Manufacturing Practices (cGMP)-compliant services for pre-clinical and clinical development, manufacturing, and eventual commercialization of cellular therapies for clients throughout the world. For more information, please visit http://www.progenitorcelltherapy.com.

Contact:
George S. Goldberger
Chief Business Officer
(201) 883-5314
ggoldberger(@)progenitorcelltherapy.com

This press release does not constitute an offer to sell, or a solicitation of any offer to buy any securities of Progenitor Cell Therapy. In addition, certain of the statements in this press release are forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and similar matters. These statements involve known and unknown risks, uncertainties, and other factors that may cause the company or its industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "intend," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue" or the negative of such terms or other comparable terminology. Forward-looking statements are only predictions. Actual events or results may differ materially. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither the company nor any other person assumes responsibility for the accuracy and completeness of such statements. The company is under no duty to update any of the forward-looking statements after the date of this press release to conform such statements to actual results.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

George S. Goldberger
Visit website